Axonics receives fda approval for fourth-generation rechargeable sacral neuromodulation system

Irvine, calif.--( business wire )--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the u.s. food and drug administration has approved the company's fourth-generation rechargeable sacral neuromodulation system.

AXNX Ratings Summary

AXNX Quant Ranking